DE2708008C3 - Verfahren zur Herstellung von 1-N-substituierten Kanamycinen, zur 1-N-Substitution eingesetzte cyclische Urethane und Verfahren zu deren Herstellung - Google Patents

Verfahren zur Herstellung von 1-N-substituierten Kanamycinen, zur 1-N-Substitution eingesetzte cyclische Urethane und Verfahren zu deren Herstellung

Info

Publication number
DE2708008C3
DE2708008C3 DE2708008A DE2708008A DE2708008C3 DE 2708008 C3 DE2708008 C3 DE 2708008C3 DE 2708008 A DE2708008 A DE 2708008A DE 2708008 A DE2708008 A DE 2708008A DE 2708008 C3 DE2708008 C3 DE 2708008C3
Authority
DE
Germany
Prior art keywords
amino
group
benzyl
solution
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2708008A
Other languages
German (de)
English (en)
Other versions
DE2708008A1 (de
DE2708008B2 (de
Inventor
Barry Clive Birchington Kent Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp
Original Assignee
Pfizer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp filed Critical Pfizer Corp
Publication of DE2708008A1 publication Critical patent/DE2708008A1/de
Publication of DE2708008B2 publication Critical patent/DE2708008B2/de
Application granted granted Critical
Publication of DE2708008C3 publication Critical patent/DE2708008C3/de
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/061,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/081,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/101,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE2708008A 1976-02-25 1977-02-24 Verfahren zur Herstellung von 1-N-substituierten Kanamycinen, zur 1-N-Substitution eingesetzte cyclische Urethane und Verfahren zu deren Herstellung Expired DE2708008C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7529/76A GB1529243A (en) 1976-02-25 1976-02-25 Process for the preparation of aminoglycoside derivatives and cyclic urethane intermediates for use therein

Publications (3)

Publication Number Publication Date
DE2708008A1 DE2708008A1 (de) 1977-09-01
DE2708008B2 DE2708008B2 (de) 1981-07-02
DE2708008C3 true DE2708008C3 (de) 1982-04-22

Family

ID=9834870

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2708008A Expired DE2708008C3 (de) 1976-02-25 1977-02-24 Verfahren zur Herstellung von 1-N-substituierten Kanamycinen, zur 1-N-Substitution eingesetzte cyclische Urethane und Verfahren zu deren Herstellung

Country Status (26)

Country Link
US (1) US4107435A (US20080293856A1-20081127-C00150.png)
JP (1) JPS52111545A (US20080293856A1-20081127-C00150.png)
AR (1) AR215616A1 (US20080293856A1-20081127-C00150.png)
AT (1) AT348123B (US20080293856A1-20081127-C00150.png)
BE (1) BE851777A (US20080293856A1-20081127-C00150.png)
CA (1) CA1071624A (US20080293856A1-20081127-C00150.png)
CH (1) CH618706A5 (US20080293856A1-20081127-C00150.png)
CS (2) CS195714B2 (US20080293856A1-20081127-C00150.png)
DD (2) DD135200A5 (US20080293856A1-20081127-C00150.png)
DE (1) DE2708008C3 (US20080293856A1-20081127-C00150.png)
DK (1) DK82177A (US20080293856A1-20081127-C00150.png)
EG (1) EG12650A (US20080293856A1-20081127-C00150.png)
ES (1) ES456304A1 (US20080293856A1-20081127-C00150.png)
FI (1) FI770568A (US20080293856A1-20081127-C00150.png)
FR (2) FR2351109A1 (US20080293856A1-20081127-C00150.png)
GB (1) GB1529243A (US20080293856A1-20081127-C00150.png)
GR (1) GR66424B (US20080293856A1-20081127-C00150.png)
HU (1) HU179565B (US20080293856A1-20081127-C00150.png)
IE (1) IE44885B1 (US20080293856A1-20081127-C00150.png)
LU (1) LU76829A1 (US20080293856A1-20081127-C00150.png)
NL (2) NL166265C (US20080293856A1-20081127-C00150.png)
PL (2) PL102193B1 (US20080293856A1-20081127-C00150.png)
PT (1) PT66229B (US20080293856A1-20081127-C00150.png)
RO (1) RO76081A (US20080293856A1-20081127-C00150.png)
SE (1) SE7702066L (US20080293856A1-20081127-C00150.png)
SU (1) SU659092A3 (US20080293856A1-20081127-C00150.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5461151A (en) * 1977-10-25 1979-05-17 Shionogi & Co Ltd Novel aminoglycoside derivative
US4327087A (en) * 1978-01-16 1982-04-27 Schering Corporation Stabilized Netilmicin formulations
US4223022A (en) * 1978-01-16 1980-09-16 Schering Corporation Stabilized aminoglycoside antibiotic formulations
JPS5538345A (en) * 1978-09-11 1980-03-17 Shionogi & Co Ltd Novel aminoglycoside derivative
US4226980A (en) * 1978-12-07 1980-10-07 Abbott Laboratories Novel derivatives of fortimicin B and process for preparing same
DE2924659A1 (de) * 1979-06-19 1981-01-22 Bayer Ag Pseudotrisaccharide, ihre herstellung und verwendung als arzneimittel
DE3000841A1 (de) * 1980-01-11 1981-07-16 Bayer Ag, 5090 Leverkusen Isolierung und reinigung von aminoglycosid-antibiotiaka
DE3101376A1 (de) * 1981-01-17 1982-09-02 Bayer Ag, 5090 Leverkusen Sisomicin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4427663A (en) 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US8314071B2 (en) * 2007-12-21 2012-11-20 Massachusetts Institute Of Technology Bioactive molecules from co-cultivation of microbes
WO2018005964A1 (en) * 2016-07-01 2018-01-04 Wake Forest University Health Sciences Modified carbohydrates, compositions comprising the same, and methods of making and using the same
US10766970B2 (en) 2016-07-01 2020-09-08 Wake Forest University Health Sciences Modified carbohydrates, compositions comprising the same, and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399118A (en) * 1942-02-13 1946-04-23 Mallinckrodt Chemical Works 2-oxazolidone compounds and method for preparing the same
SE324857B (US20080293856A1-20081127-C00150.png) * 1962-04-03 1970-06-15 Rit Rech Ind Therapeut

Also Published As

Publication number Publication date
IE44885L (en) 1977-08-25
DE2708008A1 (de) 1977-09-01
SE7702066L (sv) 1977-08-26
CH618706A5 (US20080293856A1-20081127-C00150.png) 1980-08-15
AR215616A1 (es) 1979-10-31
NL166265C (nl) 1981-07-15
BE851777A (fr) 1977-08-24
FR2351109B1 (US20080293856A1-20081127-C00150.png) 1981-07-24
JPS52111545A (en) 1977-09-19
RO76081A (ro) 1981-08-17
CA1071624A (en) 1980-02-12
PT66229B (en) 1978-07-17
FR2351127A1 (fr) 1977-12-09
DE2708008B2 (de) 1981-07-02
CS195714B2 (en) 1980-02-29
PL102193B1 (pl) 1979-03-31
HU179565B (en) 1982-11-29
GR66424B (US20080293856A1-20081127-C00150.png) 1981-03-20
PT66229A (en) 1977-03-01
CS195715B2 (en) 1980-02-29
AT348123B (de) 1979-01-25
PL103737B1 (pl) 1979-07-31
IE44885B1 (en) 1982-05-05
US4107435A (en) 1978-08-15
DD135200A5 (de) 1979-04-18
ES456304A1 (es) 1978-01-16
NL7901693A (nl) 1979-07-31
SU659092A3 (en) 1979-04-25
EG12650A (en) 1979-06-30
FI770568A (US20080293856A1-20081127-C00150.png) 1977-08-26
FR2351109A1 (fr) 1977-12-09
NL7701980A (nl) 1977-08-29
GB1529243A (en) 1978-10-18
DK82177A (da) 1977-08-26
LU76829A1 (US20080293856A1-20081127-C00150.png) 1978-10-18
DD130150A5 (de) 1978-03-08
ATA116777A (de) 1978-06-15
NL166265B (nl) 1981-02-16
FR2351127B1 (US20080293856A1-20081127-C00150.png) 1981-06-12

Similar Documents

Publication Publication Date Title
DE2708008C3 (de) Verfahren zur Herstellung von 1-N-substituierten Kanamycinen, zur 1-N-Substitution eingesetzte cyclische Urethane und Verfahren zu deren Herstellung
DE2726712C2 (US20080293856A1-20081127-C00150.png)
EP0030295B1 (de) Verfahren zur Herstellung von 4'-Epidaunorubicin, 3',4'-Diepidaunorubicin, hierbei entstehende Zwischenprodukte sowie deren Verwendung
CH633544A5 (de) Verfahren zur herstellung von thiazolessigsaeureverbindungen.
DE2716533C3 (de) N-Acetylierte oder -halogenacetylierte Kanamycine A und B, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2830469A1 (de) Herstellung von l-desoxy-nojirimycin und n-substituierten derivaten
DE2427096A1 (de) 2-deoxystreptamin-aminoglycoside und verfahren zu ihrer herstellung
DE2502935A1 (de) Verfahren zur herstellung von 1-n- eckige klammer auf l-(-)-alpha-hydroxygamma-aminobutyryl eckige klammer zu -xk-62-2
DE1917874B2 (de) 14-Halogendaunomycine, Verfahren zu ihrer Herstellung und deren Verwendung zur Herstellung von Adriamycin
DE2655731A1 (de) Neues verfahren zur herstellung von 3', 4'-dideoxykanamycin b
EP0000057B1 (de) Selektiv geschützte 4,6-Di-O-(aminoglycosyl)-1,3-diaminocyclitole
DE2322576A1 (de) Antibiotische derivate und verfahren zu deren herstellung
DE2855348A1 (de) Fortimycin a-derivate und ihre verwendung
DE2617597A1 (de) Verfahren zur herstellung von alpha-substituierten 1-n-(w-aminoacyl)- 3'-deoxyribostamycinen
DE2756057C2 (US20080293856A1-20081127-C00150.png)
DE2855350A1 (de) Fortimicin b-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3227178C2 (de) 2'-Modifizierte Kanamycine, Verfahren zu deren Herstellung und diese Verbindungen enthaltende antibakterielle Mittel
DE2458921B2 (de) N-(2-hydroxy-4-aminobutyryl)-derivate des antibiotikums xk-62-2, ihre salze, verfahren zu ihrer herstellung und arzneimittel
DE2534982B2 (de) 1-n- eckige klammer auf (l)-2-hydroxy-5-aminovaleroyl eckige klammer zu- und 1-n- eckige klammer auf (l)-2-hydroxy-6-aminocaproyl eckige klammer zu -xk-62-2, deren pharmazeutisch vertraegliche saeureadditionssalze und verfahren zu deren herstellung
DE2553626A1 (de) Antibakterielle mittel
DE3106463C2 (de) Verfahren zur Herstellung von Derivaten des Kanamycin A
DE2902292C2 (de) Verfahren zur Herstellung von 2,4-Diaminobuttersäure oder 4-Amino-2-hydroxybuttersäure
EP0854857A1 (de) Verfahren zur herstellung von optisch aktiven alpha-aminosäuren und alpha-aminosäure-derivaten
DE2012022C3 (de) Pivaloyloxymethyl- a -amino-phydroxybenzylpenicillinat und Verfahren zu seiner Herstellung
DE2747573A1 (de) 4-(3-amino-3-carboxypropoxy)phenylglyoxylsaeuren und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee